Dennis S Charney

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7473057/publications.pdf

Version: 2024-02-01

70 papers

3,558 citations

257450 24 h-index 214800 47 g-index

79 all docs

79 docs citations

79 times ranked 4698 citing authors

#	Article	IF	CITATIONS
1	Efficacy of Intravenous Ketamine for Treatment of Chronic Posttraumatic Stress Disorder. JAMA Psychiatry, 2014, 71, 681.	11.0	466
2	A Randomized Controlled Trial of Intranasal Ketamine in Major Depressive Disorder. Biological Psychiatry, 2014, 76, 970-976.	1.3	369
3	Ketamine: A Paradigm Shift for Depression Research and Treatment. Neuron, 2019, 101, 774-778.	8.1	271
4	Ketamine Treatment and Global Brain Connectivity in Major Depression. Neuropsychopharmacology, 2017, 42, 1210-1219.	5.4	240
5	Screening and Management of Depression in Patients With Cardiovascular Disease. Journal of the American College of Cardiology, 2019, 73, 1827-1845.	2.8	182
6	Machine Learning to Predict Mortality and Critical Events in a Cohort of Patients With COVID-19 in New York City: Model Development and Validation. Journal of Medical Internet Research, 2020, 22, e24018.	4.3	174
7	Psychosocial facets of resilience: implications for preventing posttrauma psychopathology, treating trauma survivors, and enhancing community resilience. Högre Utbildning, 2014, 5, .	3.0	158
8	The Biology of Human Resilience: Opportunities for Enhancing Resilience Across the Life Span. Biological Psychiatry, 2019, 86, 443-453.	1.3	154
9	Attention Bias Variability and Symptoms of Posttraumatic Stress Disorder. Journal of Traumatic Stress, 2014, 27, 232-239.	1.8	145
10	Understanding resilience: New approaches for preventing and treating PTSD. Experimental Neurology, 2016, 284, 119-132.	4.1	144
11	Reduced global functional connectivity of the medial prefrontal cortex in major depressive disorder. Human Brain Mapping, 2016, 37, 3214-3223.	3.6	125
12	A Randomized Controlled Trial of Repeated Ketamine Administration for Chronic Posttraumatic Stress Disorder. American Journal of Psychiatry, 2021, 178, 193-202.	7.2	122
13	Neurocognitive Effects of Ketamine and Association with Antidepressant Response in Individuals with Treatment-Resistant Depression: A Randomized Controlled Trial. Neuropsychopharmacology, 2015, 40, 1084-1090.	5.4	117
14	The role of the locus coeruleus in the generation of pathological anxiety. Brain and Neuroscience Advances, 2020, 4, 239821282093032.	3.4	102
15	Use of Physiological Data From a Wearable Device to Identify SARS-CoV-2 Infection and Symptoms and Predict COVID-19 Diagnosis: Observational Study. Journal of Medical Internet Research, 2021, 23, e26107.	4.3	91
16	The Case for Shifting Borderline Personality Disorder to Axis I. Biological Psychiatry, 2008, 64, 653-659.	1.3	74
17	Neuropeptide Y, resilience, and PTSD therapeutics. Neuroscience Letters, 2017, 649, 164-169.	2.1	62
18	A Randomized Dose-Ranging Study of Neuropeptide Y in Patients with Posttraumatic Stress Disorder. International Journal of Neuropsychopharmacology, 2018, 21, 3-11.	2.1	56

#	Article	IF	CITATIONS
19	The emergence of ketamine as a novel treatment for posttraumatic stress disorder. Advances in Pharmacology, 2020, 89, 261-286.	2.0	48
20	Dextromethorphan/quinidine pharmacotherapy in patients with treatment resistant depression: A proof of concept clinical trial. Journal of Affective Disorders, 2017, 218, 277-283.	4.1	41
21	COVID-19 Pandemic Support Programs for Healthcare Workers and Implications for Occupational Mental Health: A Narrative Review. Psychiatric Quarterly, 2022, 93, 227-247.	2.1	35
22	Lithium continuation therapy following ketamine in patients with treatment resistant unipolar depression: a randomized controlled trial. Neuropsychopharmacology, 2019, 44, 1812-1819.	5 . 4	32
23	Acute delivery of attention bias modification training (ABMT) moderates the association between combat exposure and posttraumatic symptoms: A feasibility study. Biological Psychology, 2017, 122, 93-97.	2.2	31
24	The impact of time spent on the electronic health record after work and of clerical work on burnout among clinical faculty. Journal of the American Medical Informatics Association: JAMIA, 2021, 28, 938-947.	4.4	31
25	Exploratory genome-wide association analysis of response to ketamine and a polygenic analysis of response to scopolamine in depression. Translational Psychiatry, 2018, 8, 280.	4.8	26
26	A Resilience-Building App to Support the Mental Health of Health Care Workers in the COVID-19 Era: Design Process, Distribution, and Evaluation. JMIR Formative Research, 2021, 5, e26590.	1.4	26
27	A Randomized Controlled Trial of Intranasal Neuropeptide Y in Patients With Major Depressive Disorder. International Journal of Neuropsychopharmacology, 2020, 23, 783-790.	2.1	23
28	Unmedicated, remitted patients with major depression have decreased serum immunoglobulin A. Neuroscience Letters, 2012, 520, 1-5.	2.1	21
29	A prospective cohort study of the psychological consequences of the COVID-19 pandemic on frontline healthcare workers in New York City. International Archives of Occupational and Environmental Health, 2022, 95, 1279-1291.	2.3	20
30	Neuroimaging correlates and predictors of response to repeated-dose intravenous ketamine in PTSD: preliminary evidence. Neuropsychopharmacology, 2021, 46, 2266-2277.	5.4	19
31	A Call to Protect the Health Care Workers Fighting COVID-19 in the United States. American Journal of Psychiatry, 2020, 177, 900-901.	7.2	17
32	A randomized, controlled pilot trial of the Emotional Faces Memory Task: a digital therapeutic for depression. Npj Digital Medicine, 2018, 1 , .	10.9	16
33	Factors Associated With Longitudinal Psychological and Physiological Stress in Health Care Workers During the COVID-19 Pandemic: Observational Study Using Apple Watch Data. Journal of Medical Internet Research, 2021, 23, e31295.	4.3	15
34	Resilience: The role of accurate appraisal, thresholds, and socioenvironmental factors. Behavioral and Brain Sciences, 2015, 38, e122.	0.7	14
35	Whole blood transcriptional signatures associated with rapid antidepressant response to ketamine in patients with treatment resistant depression. Translational Psychiatry, 2022, 12, 12.	4.8	14
36	Corticotropin-Releasing Factor Type 1 Receptor Antagonists for Stress-Related Disorders: TimeÂto Call It Quits?. Biological Psychiatry, 2017, 82, 858-860.	1.3	13

#	Article	IF	CITATIONS
37	Association of Optimism with Cardiovascular Events and All-Cause Mortality: Systematic Review and Meta-Analysis. American Journal of Medicine, 2022, 135, 856-863.e2.	1.5	10
38	Psychological Resilience in Frontline Health Care Workers During the Acute Phase of the COVID-19 Pandemic in New York City. Journal of Clinical Psychiatry, 2020, 82, .	2.2	9
39	Altered gene expression and PTSD symptom dimensions in World Trade Center responders. Molecular Psychiatry, 2022, 27, 2225-2246.	7.9	9
40	Altered cerebral benzodiazepine receptor binding in post-traumatic stress disorder. Translational Psychiatry, 2018, 8, 206.	4.8	8
41	Resilience for Frontline Health Care Workers: Evidence-Based Recommendations. American Journal of Medicine, 2021, 134, 829-830.	1.5	5
42	The Psychiatric Burden on Medical Students in New York City Entering Clinical Clerkships During the COVID-19 Pandemic. Psychiatric Quarterly, 2022, 93, 419-434.	2.1	4
43	Cognitive and emotional flexibility. , 2012, , 165-183.		3
44	Building Resilience and Well-Being in Health Care Workers in the COVID-19 Era. Journal of Clinical Psychiatry, 2021, 82, .	2.2	3
45	Developments in the first year of a resilience-focused program for health care workers. Psychiatry Research, 2021, 306, 114280.	3.3	3
46	What is resilience?. , 2012, , 1-24.		2
47	Initial Evidence for Brain Plasticity Following a Digital Therapeutic Intervention for Depression. Chronic Stress, 2019, 3, 247054701987788.	3.4	2
48	Role of nitric oxide signaling in the antidepressant mechanism of action of ketamine: A randomized controlled trial. Journal of Psychopharmacology, 2021, 35, 124-127.	4.0	2
49	Facing Fear: An Adaptive Response. , 0, , 63-84.		1
50	Cognitive and emotional flexibility., 0,, 141-157.		0
51	Optimism. , 0, , 21-38.		0
52	Facing fear. , 0, , 39-54.		0
53	Moral compass, ethics, and altruism., 0,, 55-68.		0
54	Religion and spirituality. , 0, , 69-84.		0

#	Article	IF	CITATIONS
55	Brain fitness. , 0, , 122-140.		O
56	Further Information about Posttraumatic Stress Disorder., 0,, 184-187.		0
57	Role models. , 0, , 98-108.		o
58	Role Models: Providing the Road Map. , 0, , 158-174.		O
59	Optimism: Belief in a Brighter Future. , 0, , 35-62.		0
60	Moral Compass, Ethics, and Altruism: Doing What Is Right., 0,, 85-109.		0
61	Religion and Spirituality: Drawing on Faith. , 0, , 110-135.		O
62	Training: Physical Fitness and Strengthening. , 0, , 175-198.		0
63	Brain Fitness: Challenge Your Mind and Heart. , 0, , 199-225.		O
64	Meaning, Purpose, and Growth., 0,, 251-267.		0
65	The Practice of Resilience. , 0, , 268-294.		O
66	Further Information About Posttraumatic Stress Disorder. , 0, , 295-299.		0
67	Social Support: Learning the Tap Code. , 0, , 136-157.		O
68	Community Resilience., 0,, 300-313.		0
69	What Is Resilience?. , 0, , 1-34.		0
70	Cognitive and Emotional Flexibility. , 0, , 226-250.		0